{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T04:43:25Z","timestamp":1759812205620,"version":"build-2065373602"},"reference-count":11,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Rationale<\/jats:title><jats:p>Endometrial carcinoma (EC) increasingly affects younger women, prompting interest in fertility-sparing treatments. Although hormonal therapy is a feasible option for carefully selected patients, there remains a substantial risk of recurrence or associated ovarian malignancy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>A 35-year-old premenopausal woman reported abnormal uterine bleeding characterized by increased menstrual flow over approximately one year.<\/jats:p><\/jats:sec><jats:sec><jats:title>Diagnosis and intervention<\/jats:title><jats:p>She was diagnosed with stage IA, grade 1 EC managed initially with high-dose oral megestrol acetate followed by a levonorgestrel-releasing intrauterine system due to intolerance. Serial endometrial biopsies demonstrated histologic remission, after which the patient elected definitive surgery with hysterectomy and bilateral salpingectomy while preserving the ovaries. Uterine pathology confirmed absence of residual carcinoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Follow-up and outcomes<\/jats:title><jats:p>During follow-up, a right adnexal cystic-solid mass was detected and categorized as Ovarian-Adnexal Reporting and Data System (O-RADS) ultrasound category 4, with MRI features raising suspicion. Comprehensive surgical staging confirmed a unilateral low-grade ovarian endometrioid carcinoma with squamous differentiation; staging and peritoneal cytology were negative. The patient recovered uneventfully and remains under surveillance without adjuvant therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Lessons<\/jats:title><jats:p>This case highlights the rare occurrence of metachronous ovarian endometrioid carcinoma after successful fertility-sparing and hysterectomy, underscores the importance of shared decision-making regarding ovarian preservation, and supports risk-adapted surveillance strategies in this population.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1696640","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T04:13:35Z","timestamp":1759810415000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Ovarian endometrioid tumor occurring in a patient with early-stage, low-risk endometrial carcinoma successfully treated by fertility-sparing management"],"prefix":"10.3389","volume":"15","author":[{"given":"Shuxu","family":"Tian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huangbei","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenchen","family":"Geng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00323-3","article-title":"Endometrial cancer","volume":"399","author":"Crosbie","year":"2022","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ygyno.2024.09.015","article-title":"Risk factors for the recurrence in patients with early endometrioid endometrial cancer achieving complete remission for fertility-sparing hormonal treatment","volume":"191","author":"Jang","year":"2024","journal-title":"Gynecol Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2017.08.007","article-title":"All-cause mortality in young women with endometrial cancer receiving progesterone therapy","volume":"217","author":"Ruiz","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"B4","unstructured":"Clinical Practice Guidelines in Oncology-Uterine Neoplasms\n          \n          2025"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-023-07077-7","article-title":"Prognosis of patients with endometrial cancer or atypical endometrial hyperplasia after complete remission with fertility-sparing therapy","volume":"308","author":"Ga","year":"2023","journal-title":"Arch Gynecol Obstet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/IGC.0000000000000857","article-title":"Survival impact of ovarian preservation on women with early-stage endometrial cancer: A systematic review and meta-analysis","volume":"27","author":"Gu","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2012.08.011","article-title":"Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis","volume":"207","author":"Gallos","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.5468\/ogs.19169","article-title":"Fertility-sparing treatment in early endometrial cancer: current state and future strategies","volume":"63","author":"Obermair","year":"2020","journal-title":"Obstet Gynecol Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2018.01.030","article-title":"Risk factors for ovarian involvement in young and premenopausal endometrioid endometrial cancer patients","volume":"222","author":"Li","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2025.36.e104","article-title":"Characteristics of endometrial cancer progressed to extrauterine lesions following fertility preserving medroxyprogesterone acetate therapy for young endometrial cancer patients","volume":"36","author":"Kitazawa","year":"2025","journal-title":"J Gynecol Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1763","article-title":"A proteogenomic view of synchronous endometrioid endometrial and ovarian cancer","volume":"31","author":"Coscia","year":"2025","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1696640\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T04:13:38Z","timestamp":1759810418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1696640\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":11,"alternative-id":["10.3389\/fonc.2025.1696640"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1696640","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"article-number":"1696640"}}